ArticleOrphanet journal of rare diseases2026
Persistent glutamate increase in TANGO2 deficiency with normalization after vitamin supplementation: first documentation by MR spectroscopy.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTANGO2 deficiency is a rare inherited metabolic disorder characterized by recurrent metabolic crises, rhabdomyolysis, arrhythmias, and encephalopathy. Recent studies suggest that TANGO2 functions as a mitochondrial lipid-acyl-CoA handling protein. Nonetheless, the cerebral metabolic abnormalities underlying neurological deterioration remain elusive. In this study, we present the first longitudinal evaluation of brain metabolism using proton magnetic resonance spectroscopy (MRS) before and after vitamin therapy, during the acute, subacute, and post-treatment phases, highlighting improved clinical manifestations following treatment.
methodsWe longitudinally evaluated cerebral metabolites using MRS during the acute, subacute, and post-treatment phases.
resultsA 2-year-old boy with genetically confirmed TANGO2 deficiency presented with a metabolic crisis, status epilepticus, and rhabdomyolysis (CK peak, 282,695 U/L). Despite the absence of structural abnormalities on the magnetic resonance imaging conducted on day 2, MRS revealed markedly increased glutamate (Glu; 11.51 mM; reference: 6.70 ± 0.59) with normal glutamine (Gln). On day 50, despite clinical stabilization, Glu levels remained abnormally high (9.29 mM), indicating a persistent dysfunction of the cerebral Glu–Gln cycle. Upon initiation of vitamin supplementation, including that of all eight B vitamins (i.e. B₁, B₂, B₃, B₅, B₆, B₇, B₉, and B₁₂) at the age of 3, no further crises occurred. Follow-up MRS at the age of 4 demonstrated Glu normalization (7.20 mM; reference: 6.50 ± 0.70).
conclusionsThis case provides pioneering in vivo evidence of sustained cerebral Glu accumulation in a patient with TANGO2 deficiency along with improvement after metabolic therapy. Our results suggest that the impairment of energy-dependent Glu–Gln cycling and astrocytic Glu clearance might constitute a potential mechanism underlying neurological vulnerability in TANGO2 deficiency. Longitudinal MRS may allow metabolic instability and treatment responsiveness monitoring in this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.